Skip to main content
TipRanks
Go Ultimate75% OFF

TG Therapeutics (NKB2) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

NKB2 Analyst Ratings

Moderate Buy
6Ratings
5Buy0Hold1Sell
Based on 6 analysts giving stock ratings to TG Therapeutics in the past 3 months

NKB2 Stock 12 Month Forecast

€68.08▲(16.97% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is EUR 68.08 with a high forecast of EUR 76.63 and a low forecast of EUR 63.26. The average price target represents a 16.97% change from the last price of EUR 58.20.
Highest Price Target€76.63Average Price Target€68.08Lowest Price Target€63.26

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:NKB2
Price TargetArticle
Evercore ISI€65.05→€63.26buy8.70%UpsideReiterated11/10/26
Bank of America Securities―sell―Reiterated11/10/26
TD Cowen€66.83buy14.82%UpsideReiterated11/09/26
J.P. Morgan€64.15buy10.23%UpsideReiterated11/09/26
H.C. Wainwright€69.50buy19.42%UpsideReiterated09/21/26
B. Riley Securities€76.63buy31.67%UpsideReiterated09/02/26
Jefferies€73.96buy27.07%UpsideReiterated07/14/26
Goldman Sachs€36.53hold-37.23%DownsideReiterated06/03/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
RZLTRezolute
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TG Therapeutics

3 Months
Emily Bodnar
Emily BodnarH.C. Wainwright
Success Rate8/11 ratings generated profit
73%
Average Return
+16.52%

Copying Emily Bodnar's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +16.52% per trade.

1 Year
Emily Bodnar
Emily BodnarH.C. Wainwright
Success Rate11/11 ratings generated profit
100%
Average Return
+55.64%

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.64% per trade.

2 Years
Success Rate14/14 ratings generated profit
100%
Average Return
+75.02%

Copying Tara Bancroft's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +75.02% per trade.

NKB2 Analyst Recommendation Trends

05101520Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for NKB2
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy77531
Buy76746
Hold31000
Sell00001
Strong Sell23210
total19171488

In the current month, NKB2 has received 7 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. NKB2 average Analyst price target in the past 3 months is 68.08.

NKB2 Financial Forecast

€-1€-0.5€0€0.5€1Q1 2026Q3 2026Q4 2026
High€0.57
Consensus€0.47
Low€0.23

NKB2 Earnings Forecast

Next quarter’s earnings estimate for NKB2 is EUR 0.47 with a range of EUR 0.23 to EUR 0.57. The previous quarter’s EPS was EUR 0.31. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€172.4M€196.5M€220.5M€244.6M€268.6MQ1 2026Q3 2026Q4 2026
High€269M
Consensus€260M
Low€239M

NKB2 Sales Forecast

Next quarter’s sales forecast for NKB2 is EUR 259.84M with a range of EUR 238.97M to EUR 268.60M. The previous quarter’s sales results were EUR 232.73M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

NKB2 Stock Forecast FAQ

What is DE:NKB2’s average 12-month price target, according to analysts?
Based on analyst ratings, TG Therapeutics’s 12-month average price target is €68.08.
What is DE:NKB2’s upside potential, based on the analysts’ average price target?
TG Therapeutics has 16.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TG Therapeutics a Buy, Sell or Hold?
TG Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.
What is TG Therapeutics’s share price target?
The average share price target for TG Therapeutics is €68.08. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €76.63, and the lowest forecast is €63.26. The average share price target represents a 16.97% increase from the current price of €58.2.
What do analysts say about TG Therapeutics?
TG Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of TG Therapeutics?
To buy shares of DE:NKB2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.